Tango Therapeutics, Inc. (NASDAQ:TNGX) Stake Increased by Wellington Management Group LLP

Wellington Management Group LLP raised its position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 110.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 170,228 shares of the company's stock after purchasing an additional 89,481 shares during the period. Wellington Management Group LLP owned 0.17% of Tango Therapeutics worth $1,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. AJOVista LLC purchased a new stake in shares of Tango Therapeutics in the 4th quarter valued at approximately $61,000. Cowen AND Company LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at $99,000. China Universal Asset Management Co. Ltd. grew its position in shares of Tango Therapeutics by 421.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company's stock valued at $117,000 after buying an additional 9,530 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at $136,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Tango Therapeutics by 570.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,902 shares of the company's stock valued at $138,000 after buying an additional 11,829 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Price Performance

Shares of TNGX stock traded down $0.89 during mid-day trading on Tuesday, hitting $8.11. The stock had a trading volume of 791,896 shares, compared to its average volume of 671,885. Tango Therapeutics, Inc. has a fifty-two week low of $2.88 and a fifty-two week high of $13.03. The firm has a market cap of $866.02 million, a PE ratio of -7.17 and a beta of 0.83. The company's 50-day simple moving average is $7.86 and its 200-day simple moving average is $9.27.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). Tango Therapeutics had a negative return on equity of 44.35% and a negative net margin of 299.88%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. On average, analysts expect that Tango Therapeutics, Inc. will post -1.31 EPS for the current year.

Insider Transactions at Tango Therapeutics

In other news, insider Mva Investors, Llc sold 110,731 shares of the firm's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $8.87, for a total value of $982,183.97. Following the completion of the sale, the insider now owns 203,793 shares in the company, valued at approximately $1,807,643.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 337,731 shares of company stock worth $2,700,684. Company insiders own 6.20% of the company's stock.

Analysts Set New Price Targets

TNGX has been the topic of a number of recent analyst reports. HC Wainwright dropped their target price on shares of Tango Therapeutics from $16.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, May 28th. Wedbush dropped their target price on shares of Tango Therapeutics from $18.00 to $11.00 and set an "outperform" rating on the stock in a research report on Thursday, May 23rd. Cantor Fitzgerald began coverage on shares of Tango Therapeutics in a research note on Thursday, April 4th. They set an "overweight" rating for the company. Guggenheim upgraded shares of Tango Therapeutics to a "strong-buy" rating in a research note on Tuesday, May 28th. Finally, Barclays decreased their price target on shares of Tango Therapeutics from $18.00 to $13.00 and set an "overweight" rating for the company in a research note on Friday, May 24th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $14.17.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.